Shares of Cadila Healthcare soared nearly 3 per cent on the Bombay stock Exchange after drug major said that it has received the tentative approval from the United States Food and Drug Administration (USFDA) to market Fingolimod Capsules. Boosted by the development, shares of company gained as much as 2.87 per cent to hit intra-day high of Rs 545.40 apiece on the Bombay Stock Exchange.
The stocks were currently trading at Rs 534.70 against previous close price of Rs 530.15. In a similar fashion, shares of the company were trading 0.78 per cent higher at Rs 534.20 apiece on the National Stock Exchange. Meanwhile, the broader benchmark BSE Sensex was trading at 32,074.03, up 53.28 points, or 0.17 per cent, at 12:28 hours.